Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene + hyaluronic acid is an investigational topical combination therapy being evaluated for the treatment of mild to moderate acne vulgaris. Adapalene is a third-generation topical retinoid that acts as a selective agonist for retinoic acid receptors (RAR-β and RAR-γ), regulating gene transcription to normalize follicular epithelial differentiation and providing anti-inflammatory effects by inhibiting lipoxygenase activity. Hyaluronic acid, a naturally occurring glycosaminoglycan, is included in the regimen for its potent hydrating and anti-inflammatory properties. This combination aims to mitigate the common side effects of topical retinoids, such as erythema, dryness, and scaling, thereby improving patient adherence and overall therapeutic outcomes. Badr University is conducting clinical research to compare this combination against adapalene monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + hyaluronic acid.